Jade Biosciences, Inc.

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026

Jade Biosciences will present three posters on JADE101, its anti-APRIL antibody for IgA nephropathy, at ASN Kidney Week 2026 in Denver, October 21-25. The EVERGREEN Phase 3 trial is now expected to initiate in the fourth quarter of 2026, ahead of schedule, while interim data from the ongoing JUNIPER Phase 2 is now expected in the second quarter of 2027. No new clinical data was disclosed; the release primarily reaffirms development timelines and trial design ahead of a catalyst-heavy stretch.

•11d ago

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

Jade Biosciences presented preclinical data at EADV 2026 for JADE301, a half-life-extended anti-IFN-β antibody in development for dermatomyositis. The data showed roughly 2.5-fold higher IFN-β affinity and potency than a dazukibart comparator, an approximately 25-day subcutaneous half-life in non-human primates, and predicted human SC bioavailability of 73%–75% versus ~43%–44% for dazukibart. JADE301 was well tolerated in a GLP toxicology study at all doses tested. A Phase 1 single-ascending-dose trial in 24 healthy volunteers is expected to begin in Q4 2026, with interim data anticipated in the second half of 2027.

•1mo ago

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences reported positive interim Phase 1 data for JADE101, showing approximately 70% IgA reductions from baseline and potential for every-12-week maintenance dosing in IgA nephropathy. The company ended the quarter with $461.2 million in cash and investments, which it expects will fund operations into the fourth quarter of 2028, supported by a recently closed $172.5 million public offering. Pipeline progress continued with the initiation of dosing for JADE201 in rheumatoid arthritis and the unveiling of JADE301 for dermatomyositis, with a Phase 1 healthy volunteer trial planned for Q4 2026.

•2mo ago

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

Jade Biosciences appointed Dr. Mark Eisner, M.D., M.P.H., to its Board of Directors, effective immediately. Dr. Eisner brings over 25 years of experience, having served as Executive Vice President and Chief Medical Officer at Vir Biotechnology and holding leadership roles at Genentech/Roche and FibroGen. Jade is a clinical-stage biotechnology company focused on autoimmune diseases, with lead candidate JADE101 targeting APRIL for IgA nephropathy.

•4mo ago

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

Jade Biosciences reported positive interim Phase 1 results for JADE101, showing approximately 70% IgA reductions sustained at 12 weeks after a single dose in healthy volunteers. The data suggests JADE101 is faster, deeper, and more durable than first-generation anti-APRIL agents, with a potential dosing regimen of one injection every 12 weeks. The company is advancing JADE101 into a Phase 2 trial (JUNIPER) and plans to initiate a Phase 3 registrational trial in the first half of 2027.

•5mo ago

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

Jade Biosciences announced the first participant has been dosed in the first-in-human Phase 1 clinical trial of JADE201. JADE201 is a novel, half-life extended, afucosylated anti-BAFF receptor monoclonal antibody designed to deplete B cells via a dual mechanism of action. The randomized, placebo-controlled study evaluates single ascending doses in rheumatoid arthritis patients, with interim data expected in 2027 to inform indication prioritization.

•5mo ago

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

Jade Biosciences announced the first participant has been dosed in JUNIPER, its Phase 2 clinical trial of JADE101 for IgA nephropathy. The open-label trial will evaluate safety, tolerability, and efficacy in approximately 30 participants, with interim data expected in 2027. JADE101 is an anti-APRIL monoclonal antibody engineered for ultra-high binding affinity and a 27-day half-life, supporting subcutaneous dosing every eight weeks.

•5mo ago

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences ended Q1 with $311.3 million in cash, sufficient to fund operations into the first half of 2028, while advancing its pipeline of autoimmune therapies. The company expects to initiate a Phase 2 trial for JADE101 in IgA nephropathy in Q2 2026, with interim data expected in 2027, and start a Phase 1 trial for JADE201 in rheumatoid arthritis this quarter. Executive leadership was strengthened with the appointment of Dr. Edward R. Conner as CMO and the promotion of Dr. Andrew King to President of R&D.

•5mo ago

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

Jade Biosciences appointed Edward R. Conner, M.D. as Chief Medical Officer, effective immediately to lead the company's clinical and medical organization. Dr. Conner brings extensive experience from previous roles at Ardelyx, Third Harmonic Bio, and Genentech, where he led development for XOLAIR. His hire is aimed at supporting the advancement of Jade's pipeline of therapies for autoimmune diseases. The appointment arrives at a pivotal time as the company prepares for interim Phase 1 data for JADE101 and the initiation of a Phase 2 trial in IgA nephropathy.

•6mo ago